Dept of lymphoma and medical oncology, Shanghai Cancer Center
Dept of lymphoma and medical oncology, Shanghai Cancer Center
Shanghai, Shangai, China1 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence | Recruiting | Phase 1 / Phase 2 | 2025-05-30 | NCT06966154 |